| Active Not Recruiting | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease | Phase 2 | 2022-08-22 |
| Completed | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Pneumonia, Viral | Phase 2 | 2021-01-11 |
| Active Not Recruiting | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients Wi Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | 2020-05-28 |
| Completed | Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | Phase 1 | 2019-06-24 |
| Completed | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma Glioblastoma, Recurrent Glioblastoma, GBM | Phase 1 / Phase 2 | 2018-12-29 |
| Completed | Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers Healthy Volunteers | Phase 1 | 2018-04-11 |
| Completed | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | 2016-05-06 |
| Completed | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis, IPF | Phase 2 | 2016-03-09 |
| Completed | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease | Phase 2 | 2016-03-01 |
| Completed | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 2 | 2014-09-01 |
| Completed | Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | 2013-11-01 |
| Completed | Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients Chronic Obstructive Pulmonary Disease | Phase 1 | 2012-03-01 |
| Completed | Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease | Phase 1 | 2009-11-01 |
| Completed | Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing Asthma | Phase 2 | 2009-03-01 |
| Terminated | Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma Asthma, Status Asthmaticus | Phase 2 | 2008-06-01 |
| Completed | Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma Asthma | Phase 2 | 2008-02-01 |
| Completed | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis Interstitial Cystitis | Phase 2 | 2005-05-01 |